NCT02650648 2025-07-30Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaMemorial Sloan Kettering Cancer CenterPhase 1 Completed85 enrolled
NCT07027748 2025-07-14Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaDana-Farber Cancer InstitutePhase 1 Recruiting18 enrolled